Nafarelin

For patient information, click here.

Nafarelin

Clinical data
Pregnancy category	X
Routes of administration	Nasal spray
ATC code	H01CA02 (WHO)
Legal status
Legal status	In general: ℞ (Prescription only)
Pharmacokinetic data
Elimination half-life	2.6 to 4 hours
Excretion	renal
Identifiers
CAS Number	76932-56-4
DrugBank	APRD01129
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}
Chemical and physical data
Formula	C66H83N17O13
Molar mass	1321.6344 g/mol

WikiDoc Resources for Nafarelin
Articles
Most recent articles on Nafarelin Most cited articles on Nafarelin Review articles on Nafarelin Articles on Nafarelin in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Nafarelin Images of Nafarelin Photos of Nafarelin Podcasts & MP3s on Nafarelin Videos on Nafarelin
Evidence Based Medicine
Cochrane Collaboration on Nafarelin Bandolier on Nafarelin TRIP on Nafarelin
Clinical Trials
Ongoing Trials on Nafarelin at Clinical Trials.gov Trial results on Nafarelin Clinical Trials on Nafarelin at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Nafarelin NICE Guidance on Nafarelin NHS PRODIGY Guidance FDA on Nafarelin CDC on Nafarelin
Books
Books on Nafarelin
News
Nafarelin in the news Be alerted to news on Nafarelin News trends on Nafarelin
Commentary
Blogs on Nafarelin
Definitions
Definitions of Nafarelin
Patient Resources / Community
Patient resources on Nafarelin Discussion groups on Nafarelin Patient Handouts on Nafarelin Directions to Hospitals Treating Nafarelin Risk calculators and risk factors for Nafarelin
Healthcare Provider Resources
Symptoms of Nafarelin Causes & Risk Factors for Nafarelin Diagnostic studies for Nafarelin Treatment of Nafarelin
Continuing Medical Education (CME)
CME Programs on Nafarelin
International
Nafarelin en Espanol Nafarelin en Francais
Business
Nafarelin in the Marketplace Patents on Nafarelin
Experimental / Informatics
List of terms related to Nafarelin

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Nafarelin is a gonadotropin-releasing hormone agonist (GnRH agonist). By causing constant stimulation of the pituitary, it decreases pituitary secretion of gonadotropins luteinizing hormone (LH) and follicle stimulating hormone (FSH). Nafarelin may be used in the treatment of estrogen-dependent conditions (such as endometriosis or uterine fibroids), to treat central precocious puberty, and to control ovarian stimulation in IVF.

It is normally delivered via a nasal spray.

Nafarelin acetate is marketed by Searle under the brand name Synarel.

Side effects

Side effects of nafarelin are mostly related to the low estrogen state. Side effects include hot flashes, vaginal dryness, headaches, mood changes, and decreased interest in sex. Some patients may experience acne, muscle pain, reduced breast size, and irritation of the tissue inside the nose. These side effects should disappear after stopping the medication.

Template:WikiDoc Sources